The earnings call reflects a positive sentiment overall, with strong growth in prescriptions and revenue, a solid financial position, and effective cost-saving measures. However, there are some challenges, including potential supply disruptions and strategic shifts in sales focus.

Company Guidance -

Q3 2025

During the Phathom Pharmaceuticals second quarter 2025 earnings call, key metrics highlighted included a 49% growth in VOQUEZNA prescriptions over 14 weeks, reaching over 580,000 prescriptions filled by July 25. In Q2 alone, 173,000 prescriptions were filled, marking a 36% increase from Q1. Commercial access for VOQUEZNA remains strong, with over 80% of lives covered, and 68% of Q2 prescriptions were filled through the retail channel. The company reported $39.5 million in revenue for Q2, a 39% increase over Q1, and ended the quarter with approximately $150 million in cash. Phathom provided a full-year 2025 revenue guidance of $165 million to $175 million and communicated cost-saving measures leading to a reduction in Q2 non-GAAP operating expenses by $12 million compared to Q1. The company is on track to achieve profitability by 2026, supported by ongoing revenue growth and disciplined cost management.

Significant Growth in VOQUEZNA Prescriptions

Over 580,000 VOQUEZNA prescriptions have been filled, with a 49% growth in 14 weeks. In Q2, 173,000 prescriptions were filled, showing a 36% growth over Q1.

Positive Financial Performance

Reported $39.5 million in revenue for Q2, representing a 39% growth over Q1 revenue. The company also achieved a $12 million reduction in non-GAAP OpEx compared to Q1.

Improved Cash Position and Guidance

Ended the quarter with approximately $150 million in cash. Provided revenue guidance of $165 million to $175 million for full year 2025, above analyst consensus.

Exclusivity Achieved for VOQUEZNA

The FDA updated the Orange Book to reflect exclusivity for VOQUEZNA tablets through May 2032, potentially extending exclusivity into 2033.

Cost-Saving Initiatives

Implemented cost-saving initiatives, reducing Q2 non-GAAP operating expenses by $12 million compared to Q1, with further reductions projected.

Phathom Pharmaceuticals (PHAT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PHAT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.47 / -	-1.32	―	―	―
Aug 07, 2025	2025 (Q2)	-0.95 / -1.05	-1.56	32.69% (+0.51)
May 01, 2025	2025 (Q1)	-1.10 / -1.31	-1.42	7.75% (+0.11)
Mar 06, 2025	2024 (Q4)	-1.22 / -1.05	-1.39	24.46% (+0.34)
Nov 07, 2024	2024 (Q3)	-1.47 / -1.32	-0.76	-73.68% (-0.56)
Aug 08, 2024	2024 (Q2)	-1.32 / -1.56	-0.84	-85.71% (-0.72)	―
May 09, 2024	2024 (Q1)	-1.32 / -1.42	-0.89	-59.55% (-0.53)	―
Mar 07, 2024	2023 (Q4)	-1.08 / -1.39	-1.33	-4.51% (-0.06)	―
Nov 09, 2023	2023 (Q3)	-0.89 / -0.76	-1.32	42.42% (+0.56)	―	―
Aug 10, 2023	2023 (Q2)	-0.98 / -0.84	-1.33	36.84% (+0.49)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PHAT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$8.68	$9.40	+8.29%
May 01, 2025	$4.29	$3.36	-21.68%
Mar 06, 2025	$6.08	$5.90	-2.96%
Nov 07, 2024	$18.00	$18.50	+2.78%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Phathom Pharmaceuticals (PHAT) report earnings?

Phathom Pharmaceuticals (PHAT) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is Phathom Pharmaceuticals (PHAT) earnings time?

Phathom Pharmaceuticals (PHAT) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PHAT EPS forecast?

PHAT EPS forecast for the fiscal quarter 2025 (Q3) is -0.48.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing